Medscape19h
Anti–IL-23 Therapy Might Emerge as Best Biologic in Psoriasis if Used Early and at High Doses
In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions and protection against PsA relative to other biologics.
Medindia3h
Novartis receives third FDA approval for oral Fabhalta (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis Media Relations E-mail: [email protected] Novartis Investor Relations Central investor relations line: +41 61 ...
Advanced imaging reveals the secrets of cellular traffic control
Just as cities must carefully manage the flow of cars in and out of downtown, cells regulate the movement of molecules into ...
Le Lézard9h
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis today announced that oral Fabhalta® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria, ...